{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["102"],"submitter":["Li G"],"funding":["Wuxi City Department of Science and Technology"],"pubmed_abstract":["<h4>Background</h4>Chemoresistance is a critical factor contributing to poor prognosis in clinical patients with cancer undergoing postoperative adjuvant chemotherapy. The role of gut microbiota in mediating resistance to tumour chemotherapy remains to be investigated.<h4>Methods</h4>Patients with CRC were categorised into clinical benefit responders (CBR) and no clinical benefit responders (NCB) based on chemotherapy efficacy. Differential bacterial analysis using 16S rRNA sequencing revealed Desulfovibrio as a distinct microbe between the two groups. Employing a syngeneic transplantation model, we assessed the effect of Desulfovibrio on chemotherapy by measuring tumour burden, weight, and Ki-67 expression. We further explored the mechanisms underlying the compromised chemotherapeutic eff"],"journal":["EBioMedicine"],"pagination":["105041"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10950750"],"repository":["biostudies-literature"],"pubmed_title":["Desulfovibrio desulfuricans and its derived metabolites confer resistance to FOLFOX through METTL3."],"pmcid":["PMC10950750"],"pubmed_authors":["Li G","Liu H","Wang Q","Wang F","Yan Y","Yang C","Mao Y","Yu Y"],"additional_accession":[]},"is_claimable":false,"name":"Desulfovibrio desulfuricans and its derived metabolites confer resistance to FOLFOX through METTL3.","description":"<h4>Background</h4>Chemoresistance is a critical factor contributing to poor prognosis in clinical patients with cancer undergoing postoperative adjuvant chemotherapy. The role of gut microbiota in mediating resistance to tumour chemotherapy remains to be investigated.<h4>Methods</h4>Patients with CRC were categorised into clinical benefit responders (CBR) and no clinical benefit responders (NCB) based on chemotherapy efficacy. Differential bacterial analysis using 16S rRNA sequencing revealed Desulfovibrio as a distinct microbe between the two groups. Employing a syngeneic transplantation model, we assessed the effect of Desulfovibrio on chemotherapy by measuring tumour burden, weight, and Ki-67 expression. We further explored the mechanisms underlying the compromised chemotherapeutic eff","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-07-14T23:42:45.364Z","creation":"2025-04-05T22:29:49.74Z"},"accession":"S-EPMC10950750","cross_references":{"pubmed":["38484555"],"doi":["10.1016/j.ebiom.2024.105041"]}}